CASI Pharmaceuticals (CASIF) Prepaid Assets (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Prepaid Assets came in at $2.1 million in Q4 2025, down 26.07% YoY from $2.9 million in Q4 2024, and up 6.22% on a QoQ basis from $2.0 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Prepaid Assets (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Prepaid Assets data on file, last reported at $2.1 million in Q4 2025.
- Quarterly Prepaid Assets fell 26.07% year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (down 26.07% YoY) and the FY2025 annual result came in at $2.1 million, down 26.07% from the prior year.
- Prepaid Assets improved to $2.1 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $2.7 billion in Q1 2025 to a low of $1.7 million in Q4 2021.
- A 5-year average of $846.7 million and a median of $2.9 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets tumbled 99.89% — and 2025, when it jumped 135229.34%.
- Tracing CASIF's Prepaid Assets over 5 years: stood at $1.7 million in 2021, then jumped by 76.24% to $3.0 million in 2022, then jumped by 85950.42% to $2.6 billion in 2023, then plunged by 99.89% to $2.9 million in 2024, then dropped by 26.07% to $2.1 million in 2025.
- The last three Prepaid Assets figures came in at $2.1 million (Q4 2025), $2.0 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.14 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.71 Bn |
| Dec 31, 2024 | 2.89 Mn |
| Jun 30, 2024 | 2.11 Bn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 2.56 Bn |
| Jun 30, 2023 | 1.91 Bn |
| Dec 31, 2022 | 2.98 Mn |
| Dec 31, 2021 | 1.69 Mn |